Cargando…

Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment

Neurocognitive disorders are frequent among chronic kidney disease (CKD) patients. Identifying and characterizing cognitive impairment (CI) can help to assess the ability of adherence to CKD risk reduction strategy, identify potentially reversible causes of cognitive decline, modify pharmacotherapy,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pépin, Marion, Ferreira, Ana Carina, Arici, Mustafa, Bachman, Maie, Barbieri, Michelangela, Bumblyte, Inga Arune, Carriazo, Sol, Delgado, Pilar, Garneata, Liliana, Giannakou, Konstantinos, Godefroy, Olivier, Grodzicki, Tomasz, Klimkowicz-Mrowiec, Aleksandra, Kurganaite, Justina, Liabeuf, Sophie, Mocanu, Carmen Antonia, Paolisso, Giuseppe, Spasovski, Goce, Vazelov, Evgueniy Stefanov, Viggiano, Davide, Zoccali, Carmine, Massy, Ziad A, Więcek, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713156/ https://www.ncbi.nlm.nih.gov/pubmed/34718757 http://dx.doi.org/10.1093/ndt/gfab262

Ejemplares similares

Erratum to: Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment
por: Pépin, Marion, et al.
Publicado: (2022)

Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges
por: Zoccali, Carmine, et al.
Publicado: (2021)

Drugs with a negative impact on cognitive function (Part 1): chronic kidney disease as a risk factor
por: Liabeuf, Sophie, et al.
Publicado: (2023)

Methodological challenges and biases in the field of cognitive function among patients with chronic kidney disease
por: Giannakou, Konstantinos, et al.
Publicado: (2023)

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council
por: Zoccali, Carmine, et al.
Publicado: (2018)

Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
por: Hafez, Gaye, et al.
Publicado: (2023)

Phosphate in the Context of Cognitive Impairment and Other Neurological Disorders Occurrence in Chronic Kidney Disease
por: Rroji, Merita, et al.
Publicado: (2022)

Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?
por: Liabeuf, Sophie, et al.
Publicado: (2021)

A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community
por: Sever, Mehmet Şükrü, et al.
Publicado: (2020)

The 20th anniversary of BANTAO (Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs)
por: Polenakovic, Momir, et al.
Publicado: (2014)

Renal Anemia Control in Lithuania: Influence of Local Conditions and Local Guidelines
por: Ziginskiene, Edita, et al.
Publicado: (2013)

Assessment of Fluid Status by Bioimpedance Analysis and Central Venous Pressure Measurement and Their Association with the Outcomes of Severe Acute Kidney Injury
por: Karpavičiūtė, Justina, et al.
Publicado: (2021)

The Role of Pre- and Post-Transplant Hydration Status in Kidney Graft Recovery and One-Year Function
por: Bura, Andrejus, et al.
Publicado: (2023)

Improvement in kidney transplantation in the Balkans after the Istanbul Declaration: where do we stand today?
por: Spasovski, Goce, et al.
Publicado: (2016)

An established tradition—the Eighth Congress of the Balkan Association of Nephrology, Dialysis, Transplantation and Artificial Organs (BANTAO) Belgrade, Serbia, 16–19 September 2007
por: Spasovski, Goce, et al.
Publicado: (2008)

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
por: Rroji, Merita, et al.
Publicado: (2020)

The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu
por: Figurek, Andreja, et al.
Publicado: (2021)

FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia
por: Figurek, Andreja, et al.
Publicado: (2023)

Proteomic Approaches and Potential Applications in Autosomal Dominant Polycystic Kidney Disease and Fabry Disease
por: Rroji, Merita, et al.
Publicado: (2023)

Headache Associated with Sexual Activity—A Narrative Review of Literature
por: Ściślicki, Piotr, et al.
Publicado: (2021)

Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
por: Hutny, Michał, et al.
Publicado: (2021)

Transient cognitive impairment in the acute phase of stroke – prevalence, risk factors and influence on long-term prognosis in population of patients with stroke (research study – part of the PROPOLIS study)
por: Droś, Jakub, et al.
Publicado: (2023)

From old uraemic toxins to new uraemic toxins: place of ‘omics’
por: Massy, Ziad A, et al.
Publicado: (2018)

Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes
por: Sardu, Celestino, et al.
Publicado: (2016)

What Determines Spontaneous Physical Activity in Patients with Parkinson’s Disease?
por: Gorzkowska, Agnieszka, et al.
Publicado: (2020)

Case report on novel mutation in SPAST gene in Polish family with spastic paraplegia
por: Klimkowicz-Mrowiec, Aleksandra, et al.
Publicado: (2019)

The Utility of Next-Generation Sequencing for Identifying the Genetic Basis of Dementia
por: Klimkowicz-Mrowiec, Aleksandra, et al.
Publicado: (2021)

Risk Factors for Apathy in Polish Patients with Parkinson’s Disease
por: Gorzkowska, Agnieszka, et al.
Publicado: (2021)

Does kidney transplantation influence a form of discrimination for antihypertensive drugs prescriptions?
por: Cheddani, Lynda, et al.
Publicado: (2021)

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition
por: Rizzo, Maria Rosaria, et al.
Publicado: (2012)

Response to Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082
por: Rizzo, Maria Rosaria, et al.
Publicado: (2013)

The long-term prognosis of patients with delirium in the acute phase of stroke: PRospective Observational POLIsh Study (PROPOLIS)
por: Pasińska, Paulina, et al.
Publicado: (2019)

Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation
por: Liabeuf, Sophie, et al.
Publicado: (2018)

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?
por: El Chamieh, Carolla, et al.
Publicado: (2022)

Hyperfibrinogenemia predicts long-term risk of death after ischemic stroke
por: Swarowska, Marta, et al.
Publicado: (2014)

Delirium Post-Stroke: Short- and Long-Term Effect on Depression, Anxiety, Apathy and Aggression (Research Study—Part of PROPOLIS Study)
por: Kowalska, Katarzyna, et al.
Publicado: (2020)

Early Depression Independently of Other Neuropsychiatric Conditions, Influences Disability and Mortality after Stroke (Research Study—Part of PROPOLIS Study)
por: Kowalska, Katarzyna, et al.
Publicado: (2020)

Brain dysfunction in tubular and tubulointerstitial kidney diseases
por: Viggiano, Davide, et al.
Publicado: (2021)

Protein-Bound Uremic Toxins: New Insight from Clinical Studies
por: Liabeuf, Sophie, et al.
Publicado: (2011)

The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study
por: Locatelli, Francesco, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ga5017ktcvmdi7s8ivrq1jtdre